Beta-3 Adrenergic Agonists
On this page
Direct answer
Mirabegron (25-50 mg daily) and vibegron (75 mg daily) are beta-3 selective agonists that relax the detrusor during the storage phase — beta-3 receptors constitute about 95 percent of bladder adrenoceptors, and their cyclic-AMP-mediated relaxation increases functional capacity without the dry mouth, constipation and cognitive cloud of antimuscarinics. They are first-line alternatives in overactive bladder when anticholinergic effects are intolerable, in the elderly at risk of delirium, and can combine with antimuscarinics for refractory symptoms. Their signature cautions are dose-related blood pressure rise and interactions via CYP2D6 (mirabegron), with intravesical mirabegron an emerging paediatric option for neurogenic detrusor overactivity in spina bifida children.
What you must remember
- Mechanism map: beta-1 heart, beta-2 bronchi and vessels, beta-3 bladder, adipose tissue and (weakly) gut — detrusor relaxation during filling is beta-3's physiological job, so pharmacology imitates storage-phase physiology.
- Mirabegron dosing: 25 mg once daily, titrating to 50 mg after 4-8 weeks; reduce to 25 mg with strong CYP3A4 inhibitors, severe renal or hepatic impairment; take with or without food.
- Vibegron: 75 mg once daily regardless of meals, cleaner blood-pressure profile and fewer CYP2D6 interactions in trials — the newer alternative where available.
- Blood pressure discipline: mirabegron 50 mg raises systolic pressure by 1-2 mmHg on average — check pressure before and during therapy, and avoid in severe uncontrolled hypertension.
- Combination logic: mirabegron plus an antimuscarinic (for example solifenacin) outperforms either alone in trials — dual mechanism: block contractile muscarinic drive and enhance beta-3 relaxation.
- Filling the anticholinergic gap: no dry mouth, no constipation, no accommodation failure, no confusion — decisive in elderly patients and those on other anticholinergic drugs.
- Paediatric frontier: intravesical mirabegron has been studied in children with neurogenic detrusor overactivity (spina bifida), reducing detrusor pressures where oral antimuscarinics fail — an off-label, specialist-use fact worth hedging as emerging practice.
- Other beta-3 biology: brown-adipose thermogenesis and gallbladder relaxation — the reason beta-3 agonism was once pursued as an anti-obesity target before the bladder won.
A clinic pathway worked through
A 68-year-old woman with urgency, frequency and two-hourly nocturia has already abandoned oxybutynin for dry mouth and constipation; her MMSE is normal but she lives alone and her daughter worries about "confusion tablets". Urodynamic-minded history and a voiding diary confirm overactive bladder; urinalysis excludes infection and glucose; post-void residual is 60 mL. The switch is to mirabegron 25 mg each morning, with blood pressure checked at baseline and after a month and an explicit explanation that benefit accrues over 4-8 weeks. At review, urgency has halved, mouth is comfortable, and systolic pressure is up 4 mmHg — acceptable, monitored. If she had remained symptomatic, options would be vibegron 75 mg (if available), combination with solifenacin, or — before invasive steps — posterior tibial nerve stimulation and, in refractory cases, intradetrusor botulinum toxin with its voiding-dysfunction trade-off. A second vignette anchors the paediatric angle: a spina bifida child on clean intermittent catheterisation with high-pressure bladder despite oral antimuscarinics — specialist centres have used intravesical mirabegron instillations through the catheter to lower detrusor pressures, an evolving, off-label practice.
How the exam frames it
The receptor-distribution question leads: what percentage of bladder adrenoceptors are beta-3 (about 95 percent), and what does each subtype do to the bladder — beta-2 and beta-3 relax detrusor, alpha-1 contracts the bladder base and prostate (the tamsulosin connection). The second framing is comparative: antimuscarinics versus beta-3 agonists in overactive bladder — onset, side-effect profile, cognition, pressure — with the exam-ready aphorism that antimuscarinics block the "go" signal while beta-3 agonists strengthen the "hold" signal. The third is interaction pharmacology: mirabegron inhibits CYP2D6 (raising metoprolol and desipramine exposure) and is itself a 3A4 substrate — the kind of detail separating a distinction script from a pass script. A dark-horse question is why beta-3 agonists do not treat asthma like beta-2 agents: selectivity ratios and airway receptor density, not just "different receptor".
Frequently asked questions
How do beta-3 agonists relieve overactive bladder?
Stimulation of beta-3 receptors (about 95 percent of bladder adrenoceptors) raises cyclic AMP in detrusor smooth muscle, relaxing it during storage and increasing capacity.
What is the standard dose of mirabegron?
25 mg once daily, increased to 50 mg after 4-8 weeks if needed; 25 mg maximum with strong CYP3A4 inhibitors and in severe renal or hepatic impairment.
Which patients benefit most from a beta-3 agonist over an antimuscarinic?
Those with intolerable dry mouth or constipation, the elderly at risk of cognitive effects, and patients already burdened with anticholinergic drugs.
Does mirabegron raise blood pressure?
Yes, by about 1-2 mmHg systolic at 50 mg — blood pressure is checked before and during treatment, and uncontrolled severe hypertension is a contraindication.
Can beta-3 agonists be combined with antimuscarinics?
Yes — combination therapy (for example mirabegron with solifenacin) improves symptoms over either drug alone in trials.